By: Ariela Katz
The BOSTON trial is randomizing patients with relapsed/refractory multiple myeloma to a triplet combination of selinexor (KPT-330), bortezomib (Velcade), and dexamethasone versus a combination of bortezomib and dexamethasone.
By: Jason Harris
There is very little evidence of clinical validity or clinical utility to justify the widespread use of circulating tumor DNA assays in most patients with advanced cancer, according to a panel of experts from ASCO and the College of American Pathologists
By: Andrew D. Smith
The National Comprehensive Cancer Network has developed its first set of recommendations to help clinicians manage toxicities in the recognition of the variety of immune-related adverse events that patients receiving checkpoint blockade immunotherapy may experience.